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Abstract
Antiandrogen withdrawal response is an increasingly recognized entity in patients with metastatic
prostate cancer. To our knowledge, there have been no reports describing a durable radiologic
improvement along with prostate-specific antigen (PSA) with discontinuation of the antiandrogen
agent bicalutamide. We report a case in which a dramatic decline of serum PSA levels associated
with a dramatic improvement in radiologic disease was achieved with bicalutamide discontinuation.
Background
Cancer of the prostate is the most prevalent cancer of
American men [1]. At the time of diagnosis almost 50% of
the patients have disease that extends beyond the prostate
gland. Disseminated prostate cancer is primarily treated
by local palliative measures and by testicular androgen
ablation (medical or surgical). Non-steroidal antiandro-
gens are commonly used – either as short-term induction
therapy to blunt the surge of testosterone that follows the
initiation of luteinizing hormone-releasing hormone
(LHRH) analogues, as long-term therapy with LHRH ana-
logues or as single agent salvage treatment in men in
whom LHRH analogues or surgical castration have ceased
to control the disease. A phenomenon referred to as the
antiandrogen withdrawal syndrome or antiandrogen
withdrawal response (AAWR) occurring in men receiving
non-steroidal antiandrogens was first described in 1993
[2-4]. The AAWR is defined as a 50% decline in prostate
specific antigen (PSA) following cessation of an antian-
drogen. The pathophysiology of the phenomenon is not
completely understood. We report a very dramatic and
prolonged antiandrogen withdrawal response and discuss
the literature and recent information regarding the patho-
physiology of the AAWR.
Case presentation
The patient is a 75-year old African American man in
whom prostate adenocarcinoma was initially diagnosed
in 1996. He had been asymptomatic and had presented
with an increased prostate specific antigen (PSA) and an
enlarged prostate on physical exam. Biopsy of the prostate
revealed prostate adenocarcinoma, Gleason grade 4+5 =
9/10. His PSA at the time of diagnosis was 3105 ng/mL. A
bone scan showed no evidence of metastatic disease, and
there are no records of other imaging studies being done.
He was treated first with complete androgen blockade
(leuprolide every three months and bicalutamide). The
PSA decreased dramatically to 0.55 ng/mL in six months.
On follow-up examination, there was shrinkage of the
prostate gland. He then received external beam radiation
to the prostate gland and the pelvis with total of 5000 cGy
from June of 1997 to July of 1997. The post-treatment PSA
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palladium 103 (69 seeds, 1.36 mCi/seed) in August of
1997. His PSA, however, progressively rose: 3.9 ng/mL in
1998, 23.7 ng/mL in 1999, 81.6 ng/mL in 2000 and 144.7
ng/mL in 2001. At that time, he was found to have bladder
outlet obstruction, thought to be due to bladder calculi.
He underwent lithotripsy for bladder stones and transure-
thral resection of the prostate. Neither slides nor tissue
from this procedure are presently available. Bone scan in
June of 2001 did not show bone metastases. The serum
PSA level rose to 4944 ng/mL in June of 2003. He had
been maintained on leuprolide and bicalutamide since
1996. He was first seen at Roswell Park in June 2003. PSA
level was 5786 ng/mL. He was asymptomatic and physical
examination revealed residual mild expressive aphasia
and mild weakness in the left upper extremity due to a
remote cerebrovascular accident. His performance status
was Eastern Cooperative Oncology Group score of 0–1
and there were no other significant laboratory abnormal-
ities except for mildly elevated serum creatinine. The pros-
tate was not enlarged on physical exam. Anticipating the
possibility of an AAWR, we recommended discontinua-
tion of bilcalutmide. The PSA declined by 26% (from
5789 to 4275 ng/mL) after 45 days of antiandrogen with-
drawal. In the meantime, we obtained imaging studies to
evaluate his disease. Abdominal and pelvic CT scans
showed massive retroperitoneal, bilateral common iliac
and bilateral internal iliac adenopathy consistent with
metastatic disease (see Figure 1A). Bone scan did not show
any evidence of bone metastases. The serum PSA concen-
tration continued to decrease and two months following
discontinuation of bicalutamide it was 3376 ng/mL (45%
decline). Twelve months after discontinuing bicalutamide
the PSA reached a nadir of 3.19 ng/mL (Figure 2). Repeat
abdominal and pelvic CT scan 7 months after the discon-
tinuation of bicalutamide showed remarkable reduction
in retroperitoneal and iliac adenopathy (Figure 1B). The
patient continued to do well clinically. Twenty months
after anti-androgen withdrawal, the radiological response
was maintained on the abdominal and pelvic CT scan
(Figure 1C). Patient remained on leuprolide alone (after
biacalutamide withdrawal) for approximately 3 years till
significant increase in PSA was noted and therapy changed
to ketoconazole and hydrocortisone in addition to leu-
prolide. At the time of change of therapy (May 2006) PSA
had increased to 331 ng/ml. No significant change in the
retroperitoneal adenopathy was noted at that time on CT
imaging. Interval development of nodularity adjacent to
and contiguous with the superior aspect of the prostate
gland and a lymph node in the right obturator region were
noted, which were new. Patient was asymptomatic.
Patient was on multiple medications which interacted
with ketoconazole and patient chose to continue on
hydrocortisone alone after a short period (less than a
month). PSA declined to 222.70 ng/ml in June 2006 but
increased thereafter to 724.89 ng/ml in December 2006.
Performance status continued to decline and PSA pro-
gressed rapidly to 4008.17 ng/ml in March 2007 and to
5888.5 ng/ml in April 2007. Patient at this time decided
to restart ketoconazole in addition to hydrocortisone.
However overall condition declined rapidly and patient
was placed under hospice care and died in September
2007
Discussion
Prior case reports and clinical studies in antiandrogen 
withdrawal
Table 1 summarizes a series of reports on antiandrogen
withdrawal [5-19].
The AAWR was first described by Kelly and Scher in 1993
[5]. They described three metastatic prostate cancer
patients in whom discontinuation of the flutamide
resulted in PSA decrease (36% to 89% decline) and in
some cases symptomatic improvement. In a second report
by the same group, 36 men with metastatic prostate can-
cer who were receiving flutamide and had progressive dis-
ease were evaluated following flutamide discontinuation
[6]. Ten patients had a substantial decline (≥ 80% in 7
patients and ≥ 50% in 3) in the serum PSA level. The dura-
tion of decline was short, median of 5+ months. In a
Canadian study, the median duration of response was
14.5 months [7]. Other reports of flutamide withdrawal
response are as noted in table 1[8,9]. AAWR has also been
described following bicalutamide and nilutamide with-
drawal [10-13]. Small and colleagues compared antian-
drogen withdrawal alone or in combination with
ketoconazole in a randomized phase III trial in androgen-
independent prostate cancer patients [14]. This is the larg-
est prospective study of AAWR. One hundred thirty-two
patients were randomized to undergo androgen with-
drawal alone or with ketoconazole and hydrocortisone.
Eleven percent of patients undergoing antiandrogen with-
drawal alone experienced PSA decline = 50%. The objec-
tive response rate in a measurable disease was 2%. The
median time to PSA progression in PSA responders was
5.9 months (5.3 to 10.1 months). Of the patients had
antiandrogen withdrawal and ketoconazole, 27% had a
PSA response and 20% had objective responses. There
were no differences in survival.
Sher and colleagues suggested that there was an associa-
tion between duration of antiandrogen therapy and the
likelihood of AAWR [15]. The median duration of antian-
drogen use for patients with a PSA decline greater than
50% from the baseline was 25 months versus 16 months
of those nonresponders (p value = 0.012). Figg et al
reported that patients who responded to flutamide with-
drawal received the agent for a longer period (2.33 years)
than the non-responders (1.54 years) [16]. These differ-Page 2 of 8
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Radiographic response to Bicalutamide withdrawalFigure 1
Radiographic response to Bicalutamide withdrawal. Panel A depicts computed tomography scan of abdomen and pelvis 
with significant periaortic and retroperitoneal adenopathy about 2 months after cessation of bicalutamide. Panel B depicts dra-
matic egression of adenopathy in response to bicalutamide withdrawal after 8 months. Panel C depicts durable response 20 
months after bicalutamide withdrawal.
Journal of Hematology & Oncology 2008, 1:21 http://www.jhoonline.org/content/1/1/21ences were not statistically significant. The study from
Herrade et al did not show the significant association
between the duration of its use and withdrawal response
[8]. The median months for initial hormone therapy were
19 months for the responders and 16.5 months for the
non-responders (p = 0.41). There are no clear "predictors"
of AAWR.
Molecular mechanisms of antiandrogen withdrawal 
response
The mechanisms of AAWR are also unclear. Several pro-
posed mechanisms are depicted in Figure 3[20-28]. The
androgen receptor (AR) belongs to the steroid-receptor
superfamily. After binding to its ligand, androgen, AR
forms a homodimer and regulates androgen responsive
genes via androgen response elements. The receptor func-
tions as a transcriptional factor and together with other
co-regulatory proteins (coactivators and co-repressors)
which may associate with the AR-ligand complex control
transcriptional activity. AR consists of a c-terminal ligand
binding domain and a transactivation domain, the central
DNA binding domain and the N-terminal transactivation
domain. The AR protein can be detected even in the
androgen-independent prostate cancer and AR signaling
is believed to be important even in so-called "androgen
independent disease". One of the proposed mechanisms
of the AAWR is that it is mediated through AR mutation.
It is postulated that mutations in the ligand binding
domain can render noncanonical ligands, such as estro-
gen, hydrocortisone, or androgen receptor antagonists,
agnostic[22,23]. In vitro, hydroxyflutamide activates AR
transcriptional activity in the androgen-sensitive prostate
cancer cell line, LNCaP. In LNCaP there is a point muta-
tion in the AR, (threonine to alanine), at codon 877 in the
ligand binding domain of the AR gene [20,22]. Such
mutations have been described in tumor cells from
Effect of cessation of bicalutamide on serum PSA concentrationsFigure 2
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described the isolation of cancer cells with mutant andro-
gen receptor genes from patients with metastatic, andro-
gen-independent cancer patients [24]. When these cloned
genes were transfected into the CV-1 cells (monkey
fibroblast cell line), they responded in an agonistic fash-
ion to progesterone and estradiol. The wild type androgen
receptor is unresponsive or only weakly activated by
antiandrogens. However, a detailed study by this group
showed that only 10% of surveyed samples of tumor tis-
sue from patients with androgen independent disease
demonstrated AR mutations[25]. One hundred eighty-
four bone marrow biopsies were obtained from men
enrolled on a trial of antiandrogen withdrawal. In 48
bone marrow biopsies prostate cancer was detected. The
androgen receptors from these samples were sequenced.
Five out of 48 samples (10%) had mutated androgen
receptors. All mutations were single-base, missense substi-
tutions. Two of the mutations were located in the AF-2
domain of androgen receptor which is essential for coac-
tivator binding and its signaling. They found no correla-
tion between androgen receptor mutations and an
antiandrogen withdrawal response or survival. There was
a 20% PSA response to antiandrogen withdrawal in the
androgen receptor mutations group, compared with a 7%
PSA response in the no mutation group. The median sur-
vival in the androgen receptor mutation group was 9.2
months, compared with 11.2 months in the no mutation
group. The progression-free survival was 3.3 months in
the AR mutation group, compared with 3.1 months in the
no mutation group. Therefore, mutations alone seem
unlikely to account for all cases of androgen independent
disease and the antiandrogen withdrawal response.
It has also been suggested that antiandrogens may stimu-
late a non-androgen receptor pathway. Lee et al showed
that hydroxyflutamide can activate the mitogen-activated
protein (MAP) kinase pathway independent of androgen
receptor [26]. They showed by immunohistochemical
analysis a significant increase of activated MAP kinase in
prostate tumors from patients receiving hydroxyfluta-
mide. In vitro hydroxyflutmamide induced rapid activa-
tion of ras/MAP kinase pathway in human prostate cancer
DU145 cells (which lack the androgen receptor) as well as
in CWR22 and PC-3AR2 androgen receptor positive cells
lines, indicating that the activation did not require andro-
gen receptor. Furthermore, an epidermal growth factor
receptor inhibitor or neutralizing antibody could obliter-
ate this hydroxyflutamine-mediated activation of MAP
kinase pathway. They suggested that antiandrogen,
hydroxyflutamide could initiate the activation via a mem-
brane-initiated, non-androgen receptor-mediated action,
providing alternative pathway that might contribute to
the withdrawal syndrome. However, there is no report of
other nonsteroidal antiandrogen, bicalutamide and
nilutamide, having such stimulatory effect on the MAP
kinase pathway, limiting the generalizability of this find-
ing.
Table 1: Reports of antiandrogen withdrawal
Author Antiandrogen 
agent(s)





Duration of AAWR 
(Months)
Kelly[5] Flutamide 3 2 5–17 2–5
Collinson[17] Flutamide 1 1 12 12
Scher[6] Flutamide 36 10 NS 5*
Scher[15] Flutamide 57 16 16 5.6
Dupont[7] Flutamide† 40 32 5–7 14.5
Figg[16] Flutamide 21 7 28 3.7
Sartor[18] Flutamide† 29 14 Median: 27* 8
Herrade[8] Flutamide 39 11 Median: 19* 3.3
Small[9] Flutamide 82 12 Median: 21.5* 3.5
Small[10] Bicalutamide 1 1 32 2
Nieh[19] Bicalutamide 3 2 24–35 2–4
Schellhammer [11] Flutamide/
Bicalutamide‡





132 15 NS 5.9
Gomella[12] Nilutamide 1 1 11 3
Huan[13] Nilutamide†† 2 2 10 and 15 7 and 6
NS = not stated
* indicates median
† Adjuvant treatment with aminoglutamide and hydrocortisone
‡ 4 patients assessed for objective response at 12 weeks: 2 has stable disease
†† One patient was treated with flutamide, and then cyproterone before nilutamide; Another patient were treated with combined goserelin and 
nilutamidePage 5 of 8
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gen receptor. Taplin et al showed that all metastatic
androgen-independent tumors examined in her study
expressed high levels of androgen receptor gene tran-
scripts, relative to the levels expressed by an androgen
dependent prostate cancer cell line, LNCaP [24]. This
raises the possibility of increasing androgen receptor
expression may alter the prostate cancer cells' response to
its ligand or even its antagonists. A report by Chen et al
showed that mere 3-fold increase in androgen receptor
will confer prostate cancer cells resistance to antiandro-
gens by amplifying signal output from low levels of resid-
ual ligand, and by altering the normal response to
antagonists [27]. The study showed that when androgen
receptors were over-expressed by transfection in the pros-
tate cancer cell lines, LNCaP and LAPC4, the transfected
cells were able to grow in low androgen concentrations.
Importantly, the cell growth could also be enhanced by
the antiandrogen, bicalutamide. The possible explanation
could be an aberrant interaction between an androgen
receptor coregulatory proteins and the receptor itself. They
found that high androgen receptor levels could alter coac-
tivator assembly with subsequent effects on transcrip-
tional activity.
Most recently, studies of macrophage/cancer cell interac-
tion have provided another possible explanation for hor-
mone resistance in the androgen-independent prostate
cancer and the AAWR [28]. Zhu et al noted that all tumor
samples they examined exhibited macrophage infiltration
as well as stromal interactions with macrophages as com-
pared to much less interaction between the macrophage
and the normal areas [28]. The findings suggest modula-
tory effects of macrophages on the cancer cells through
Schematic diagram for different proposed mechanisms of antiandrogen withdrawalFigure 3
Schematic diagram for different proposed mechanisms of antiandrogen withdrawal.AR, androgen receptor, AR* 
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showed that IL-1 could convert androgen antagonists into
agonists. The IL-1 stimulation of mitogen-activated pro-
tein/ERK kinase kinases (MEKK) results in phosphoryla-
tion of TAB2, an AR-interacting protein, which resulted in
and release of the TAB2/N-CoR holocorepressor complex
from the androgen receptor. Transcriptional activity of the
androgen receptor, which was inhibited in the presence of
bicalutamide, was then turned on.
Conclusion
In conclusion, we report here one of the first and to our
knowledge most dramatic, and sustained antiandrogen
withdrawal response. This case report emphasizes this
subgroup of patients may have significant response to
antiandrogen withdrawal and benefit from a non-cyto-
toxic intervention. Identification of this group of patients
is important. Even though the exact mechanism of the
antiandrogen withdrawal is not known, the molecular
data suggest that androgen receptor still plays a crucial
role in the phenomenon. Further understanding of the
receptor biology is important.
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